White House to Announce a Deal With Pharmaceutical Company Regeneron
NOTUS — News of the United States • • business
Key Points:
- The White House is set to announce a drug pricing deal with Regeneron, the last pharmaceutical company to agree to discount drugs in exchange for tariff relief as part of a yearlong administration campaign.
- Regeneron will reduce Medicaid prices for current and future medications and sell the cholesterol-lowering drug Praluent for $225, listing it on President Trump's drug pricing portal, TrumpRx.
- The deal includes Regeneron's newly FDA-approved gene therapy Otarmeni for rare childhood hearing loss, which the company will provide for free to those in need.
- Regeneron has also committed nearly $10 billion to boost domestic manufacturing capabilities in the U.S., aligning with the administration's push for increased local production.
- Critics argue the impact of these deals may be limited since Medicaid already pays lower drug prices than Medicare and private insurers, and some companies have raised prices despite the agreements.
